Two regimens of lithium prophylaxis and renal function.
Two regimens of lithium prophylaxis with different pharmacokinetic characteristics were compared under double-blind conditions in 25 bipolar patients in remission already stabilized on lithium, to determine the relative effects of each regimen on renal function. Once-daily lithium carbonate (Priadal), which gives a peak lithium plasma level 2-3 h post-administration with a low level 24 h later, was compared with twice-daily lithium citrate (Litarex), which maintains a steadier 24 h plasma level. Patients were allocated randomly to one of the 2 regimens. They were seen monthly for clinical ratings over the course of 12 months. A comprehensive battery of renal function tests was undertaken at the start of the trial, between 6-9 months after the start and again after 1 year. No significant differences were observed in clinical outcome, side effects or renal function between the 2 regimens.
Muir
A
A
Academic Unit of Human Psychopharmacology, Medical College of St Bartholomew's Hospital, London, United Kingdom.
Davidson
R
R
Silverstone
T
T
Dawnay
A
A
Forsling
M L
ML
D000118:Acetylglucosaminidase / Q000097:blood; D001714:Bipolar Disorder / Q000188:drug therapy*; D002951:Citrates; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007677:Kidney Function Tests; D008094:Lithium / Q000008:administration & dosage / Q000009:adverse effects*; D016651:Lithium Carbonate; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D014563:Urodynamics / Q000187:drug effects; D014882:Water-Electrolyte Balance / Q000187:drug effects
D002951:Citrates; D016651:Lithium Carbonate; C070669:lithium citrate; D008094:Lithium; D003404:Creatinine; D000118:Acetylglucosaminidase